Volkswagen AG ’s chief executive officer said the restructuring process underway at Europe’s largest automaker will continue even as its order backlog rises, according to Bild am Sonntag. To avoid costly overcapacity, VW is applying “clear manufacturing cost targets” to all its plants, be they in Germany, Europe or China, Oliver Blume told the German newspaper in an interview. “We will continue to...
Volkswagen AG ’s chief executive officer said the restructuring process underway at Europe’s largest automaker will continue even as its order backlog rises, according to Bild am Sonntag. To avoid costly overcapacity, VW is applying “clear manufacturing cost targets” to all its plants, be they in Germany, Europe or China, Oliver Blume told the German newspaper in an interview. “We will continue to scrutinize capacities in the future,” Blume said. “The restructuring will continue,” he said, while defending the company’s plan to cut about 50,000 jobs in Germany by 2030. VW has a higher cost structure in its home market, including labor costs, “and we have to offset that with higher productivity,” Blume was cited as saying. “Our energy costs are too high and there’s too much regulation,” he said. “Developing and building vehicles in Germany and then exporting them doesn’t work any more because the various regions of the world have changed,” he said. VW has forecast an operating return this year as low as 4% as tariffs, spending on electric vehicles and intensifying competition from China drag on its business. Read More: VW Targets More Savings to Keep Up With Intense Competition
Sir Jim Ratcliffe’s Ineos Group is taking legal action against Sir Ben Ainslie over the boat built for the 2024 America’s Cup. Ratcliffe and Ainslie worked closely together across two cycles of the famous sailing competition, culminating in a historic but ultimately unsuccessful challenge for the title 18 months ago. The two men have since fallen out over plans for a third bid. In April 2025, Ineo...
Sir Jim Ratcliffe’s Ineos Group is taking legal action against Sir Ben Ainslie over the boat built for the 2024 America’s Cup. Ratcliffe and Ainslie worked closely together across two cycles of the famous sailing competition, culminating in a historic but ultimately unsuccessful challenge for the title 18 months ago. The two men have since fallen out over plans for a third bid. In April 2025, Ineos announced it had “reluctantly withdrawn its challenge” for next year’s race, claiming a six-month delay in reaching an agreement with Ainslie’s Athena Racing had “undermined its ability to prepare” for the event. On Saturday, Ineos released a statement on Saturday expressing “surprise” that Ainslie’s Athena Racing has kept the boat – named Britannia – which was used in 2024. Ineos Britannia became the first British team to win the challenger series but were then beaten 7-2 by Emirates Team New Zealand in Barcelona. “Ineos is surprised that the boat we built for the last America’s Cup has been taken by Athena Racing,” read the statement. “The boat belongs to Ineos and it is inappropriate to assume it can be used for the next competition without seeking our permission. View image in fullscreen Ineos Britannia race Emirates New Zealand off the coast of Barcelona in 2024. Photograph: Matteo Secci/Zuma/Shutterstock “The boat was the most successful British boat in history and cost Ineos £180million, and evolved naturally from the first boat, which cost a further £170m. Ineos is taking legal steps for the boat to be returned.” Ainslie’s team, now rebranded as GB1, will be the challenger of record for the 38th America’s Cup in Naples next year, with Oakley Capital announced as major investors in December. Later on Saturday GB1 issued a statement in response, in which they said they “appreciate the sponsorship and support of Ineos over the last two campaigns” but maintained the boat belonged to them. “It should come as no surprise to Ineos that assets which are owned by, and have...
Reddit (NYSE: RDDT) is one of the fastest-growing social media companies in the world. *Stock prices used were the afternoon prices of March 19, 2026. The video was published on March 21, 2026. Continue reading
Reddit (NYSE: RDDT) is one of the fastest-growing social media companies in the world. *Stock prices used were the afternoon prices of March 19, 2026. The video was published on March 21, 2026. Continue reading
On February 17, 2026, FCPM III Services B.V. disclosed a buy of 1,489,096 RAPT Therapeutics (NASDAQ:RAPT) shares, an estimated $46.24 million trade based on quarterly average pricing. According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, FCPM III Services B.V. increased its stake in RAPT Therapeutics (NASDAQ:RAPT) by 1,489,096 shares during the fourth quarter. The...
On February 17, 2026, FCPM III Services B.V. disclosed a buy of 1,489,096 RAPT Therapeutics (NASDAQ:RAPT) shares, an estimated $46.24 million trade based on quarterly average pricing. According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, FCPM III Services B.V. increased its stake in RAPT Therapeutics (NASDAQ:RAPT) by 1,489,096 shares during the fourth quarter. The estimated value of the new shares acquired was $46.24 million, based on the average unadjusted closing price for the quarter. At quarter-end, the total value of the position had risen by $53.22 million, reflecting both the trading activity and changes in RAPT’s share price. RAPT Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of oral small molecule drugs for cancer and inflammatory conditions. The company's strategy centers on advancing novel CCR4 antagonists and kinase inhibitors through clinical trials to address significant unmet needs in immunology and oncology. Continue reading
For several months, I had been warning investors that SoFi (NASDAQ: SOFI) stock was too expensive. Since my warnings, the stock has crashed to lower levels. *Stock prices used were the afternoon prices of March 19, 2026. The video was published on March 21, 2026. Continue reading
For several months, I had been warning investors that SoFi (NASDAQ: SOFI) stock was too expensive. Since my warnings, the stock has crashed to lower levels. *Stock prices used were the afternoon prices of March 19, 2026. The video was published on March 21, 2026. Continue reading
After becoming the first healthcare stock to hit a $1 trillion market valuation in late 2025, Eli Lilly (LLY 1.29%) hasn't performed well since, with its shares down about 19% from their 52-week high of $1133.95. Some are worried about the company's runaway valuation, while others fear that, even as the drugmaker leads the market for weight management medicines, increased competition will erode it...
After becoming the first healthcare stock to hit a $1 trillion market valuation in late 2025, Eli Lilly (LLY 1.29%) hasn't performed well since, with its shares down about 19% from their 52-week high of $1133.95. Some are worried about the company's runaway valuation, while others fear that, even as the drugmaker leads the market for weight management medicines, increased competition will erode its pricing power and depress its profits and margins. The bulls might have a different view, though, but which side is right? The expanding anti-obesity market While it's true that there will be more competition in chronic weight management, Eli Lilly's lead in this space seems safe. What's more, newer launches will help the company solidify its top position while expanding its addressable market. Take orforglipron, an oral GLP-1 candidate Eli Lilly is gearing up to launch, hopefully in the second quarter. As management noted, the only oral therapy currently approved for weight loss, oral Wegovy, is attracting new patients, likely those who did not want to take older subcutaneous weight-loss medications. Orforglipron could be a best-in-class medicine thanks to its strong clinical trial performance across both diabetes and obesity, including some studies in which it went head-to-head with other oral GLP-1s and performed better. Eli Lilly could also target an underserved niche with another candidate, retatrutide. In a phase 3 study, not only did retatrutide lead to an outstanding 28.7% mean weight loss after 68 weeks -- a number never before seen in a phase 3 clinical trial -- but it also significantly reduced knee pain. Eli Lilly will target patients with high body mass indexes -- for whom current weight-loss options often plateau, leaving them with plenty of work to do -- with this drug. Expand NYSE : LLY Eli Lilly Today's Change ( -1.29 %) $ -11.87 Current Price $ 905.63 Key Data Points Market Cap $857B Day's Range $ 899.48 - $ 925.00 52wk Range $ 623.78 - $ 1133.95 Volume ...
Key Points Eli Lilly is well-positioned to maintain its lead in the anti-obesity market. The company's newer products in this niche will help expand its reach. Eli Lilly has an attractive lineup and pipeline beyond its core area. 10 stocks we like better than Eli Lilly › After becoming the first healthcare stock to hit a $1 trillion market valuation in late 2025, Eli Lilly (NYSE: LLY) hasn't perfo...
Key Points Eli Lilly is well-positioned to maintain its lead in the anti-obesity market. The company's newer products in this niche will help expand its reach. Eli Lilly has an attractive lineup and pipeline beyond its core area. 10 stocks we like better than Eli Lilly › After becoming the first healthcare stock to hit a $1 trillion market valuation in late 2025, Eli Lilly (NYSE: LLY) hasn't performed well since, with its shares down about 19% from their 52-week high of $1133.95. Some are worried about the company's runaway valuation, while others fear that, even as the drugmaker leads the market for weight management medicines, increased competition will erode its pricing power and depress its profits and margins. The bulls might have a different view, though, but which side is right? Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » The expanding anti-obesity market While it's true that there will be more competition in chronic weight management, Eli Lilly's lead in this space seems safe. What's more, newer launches will help the company solidify its top position while expanding its addressable market. Take orforglipron, an oral GLP-1 candidate Eli Lilly is gearing up to launch, hopefully in the second quarter. As management noted, the only oral therapy currently approved for weight loss, oral Wegovy, is attracting new patients, likely those who did not want to take older subcutaneous weight-loss medications. Orforglipron could be a best-in-class medicine thanks to its strong clinical trial performance across both diabetes and obesity, including some studies in which it went head-to-head with other oral GLP-1s and performed better. Eli Lilly could also target an underserved niche with another candidate, retatrutide. In a phase 3 study, not only did retatrutide lead to an outstanding 28.7% mean wei...
Round-the-clock gyms have mushroomed across Hong Kong in recent years, offering flexibility and convenience to time-pressed people juggling work and exercise. But just like the notorious problems of aggressive sales tactics and long membership contracts with chain fitness centres in the industry’s heyday, these smaller outlets running on a new business model also come with hidden costs and privacy...
Round-the-clock gyms have mushroomed across Hong Kong in recent years, offering flexibility and convenience to time-pressed people juggling work and exercise. But just like the notorious problems of aggressive sales tactics and long membership contracts with chain fitness centres in the industry’s heyday, these smaller outlets running on a new business model also come with hidden costs and privacy issues that consumers cannot afford to ignore. A targeted investigation by the Consumer Council on 24-hour operators has exposed how simple monthly plans can conceal a maze of extra costs . Five of the 11 gyms examined had non-refundable charges such as enrolment fees and payments for electronic keys or access cards. None offered genuine “one-month membership” as advertised, and the real price for short-term memberships can be more than double the headline monthly fees. The conditions for suspending membership also vary widely. There is a sense of deja vu. Previously, the council hit out at the long binding contracts and aggressive sales tactics that locked users of chain fitness centres into disadvantaged positions. While the industry has evolved into smaller outlets with 24/7 operations, the problems with opaque fee structures and complicated tie-ins prevail. Advertisement All-day access also comes with security and privacy concerns, with users required to provide sensitive personal data to enter the premises via facial recognition or other biometric systems. The watchdog has rightly reminded gym operators to adhere to the principle of collecting “necessary and adequate but not excessive” personal data and consider less privacy-intrusive methods for sign-up and access. Consumers are also urged to scrutinise the sales and privacy terms to avoid misunderstanding and abuses. In a city where digital footprints are expanding rapidly, the collection of facial images in exchange for convenient and value-for-money fitness facilities should not be treated lightly. The onus is on ...
Key Points Kynam Capital sold 1,720,949 shares of Cogent Biosciences in the fourth quarter; the estimated transaction value was $48.38 million. Meanwhile, the position's quarter-end value changed by $105.74 million, reflecting both trading and share price movements. Post-sale, the fund held 6,165,223 shares valued at $218.99 million. 10 stocks we like better than Cogent Biosciences › Kynam Capital...
Key Points Kynam Capital sold 1,720,949 shares of Cogent Biosciences in the fourth quarter; the estimated transaction value was $48.38 million. Meanwhile, the position's quarter-end value changed by $105.74 million, reflecting both trading and share price movements. Post-sale, the fund held 6,165,223 shares valued at $218.99 million. 10 stocks we like better than Cogent Biosciences › Kynam Capital Management disclosed in a February 17, 2026, SEC filing that it sold 1,720,949 shares of Cogent Biosciences (NASDAQ:COGT), an estimated $48.38 million trade based on quarterly average pricing. What happened According to a SEC filing dated February 17, 2026, Kynam Capital Management reduced its stake in Cogent Biosciences by 1,720,949 shares during the fourth quarter. The estimated transaction value was $48.38 million, calculated using the average closing price over the quarter. The quarter-end valuation of this position changed by $105.74 million, a figure that incorporates both share sales and stock price appreciation. What else to know Kynam Capital Management, LP’s sell action left Cogent Biosciences at 13.99% of reported AUM after the trade. Top holdings after the filing: NASDAQ:COGT: $218.99 million (14.3% of AUM) NASDAQ:VERA: $173.85 million (11.3% of AUM) NASDAQ:SNDX: $169.15 million (11.0% of AUM) NASDAQ:CLDX: $161.42 million (10.5% of AUM) NASDAQ:PCVX: $134.84 million (8.8% of AUM) As of Friday, shares of Cogent Biosciences were priced at $33.38, up a staggering 360% over the past year, compared to a 15% gain for the S&P 500 in the same period. Company overview Metric Value Price (as of Friday) $33.38 Market Capitalization $5.4 billion Net Income (TTM) ($328.94 million) Company snapshot Cogent Biosciences develops precision therapies targeting genetically defined diseases, with a lead product candidate (CGT9486) focused on inhibiting the KIT D816V mutation in systemic mastocytosis and advanced gastrointestinal stromal tumors. The company operates a research-driven...
Key Points Whalen sold 26,667 shares on March 2, 2026, for a transaction value of ~$1.25 million, with an additional 650 shares gifted to charity. The transaction represented 19.9% of Whalen's direct holdings prior to the sale, reducing her direct position to 107,591 shares. All shares disposed were held directly; the transaction included the exercise of 11,667 options immediately prior to sale, w...
Key Points Whalen sold 26,667 shares on March 2, 2026, for a transaction value of ~$1.25 million, with an additional 650 shares gifted to charity. The transaction represented 19.9% of Whalen's direct holdings prior to the sale, reducing her direct position to 107,591 shares. All shares disposed were held directly; the transaction included the exercise of 11,667 options immediately prior to sale, with no indirect or trust involvement. This activity reflects routine liquidity management, with the shares sold comprising a mix of existing holdings and same-day exercised options, and Whalen retains a material direct equity stake. 10 stocks we like better than Bristow Group › SVP CFO Sells VTOL 26,667 Shares Worth $1.25 Million. Bristow Group, a global aviation services provider to offshore energy firms, reported a notable insider sale in its latest SEC filing. On March 2, 2026, Jennifer Dawn Whalen, SVP, CFO of Bristow Group Inc. (NYSE:VTOL), executed the open-market sale of 26,017 shares of common stock for a transaction value of approximately $1.22 million, as disclosed in a SEC Form 4 filing SEC Form 4 filing.This figure excludes 650 shares gifted in the same filing. Transaction summary Metric Value Shares sold (direct) 26,667 Shares gifted (direct) 650 Transaction value ~$1.25 million Post-transaction shares (direct) 107,591 Post-transaction shares (indirect) 0 Post-transaction value (direct ownership) ~$5.05 million Transaction value based on SEC Form 4 weighted average purchase price ($46.90); post-transaction value based on March 2, 2026 market close price as reported in filings.Gift shares: 650 shares gifted in this filing are excluded from all share counts, transaction values, and post-transaction balances above. Key questions What was the structure and derivative context of this transaction? The filing indicates Whalen exercised 11,667 fully vested options at $24.54, immediately selling those shares alongside approximately 14,350 shares from existing holdings. ...
Key Points Uber’s advertising business is scaling faster than expected. This jump in advertising could improve Uber’s margins. Uber’s platform gives it a structural advantage in ads. 10 stocks we like better than Uber Technologies › Investors typically think of Uber Technologies (NYSE: UBER) as a ride-hailing and food delivery company. And for good reason -- those businesses still drive the majori...
Key Points Uber’s advertising business is scaling faster than expected. This jump in advertising could improve Uber’s margins. Uber’s platform gives it a structural advantage in ads. 10 stocks we like better than Uber Technologies › Investors typically think of Uber Technologies (NYSE: UBER) as a ride-hailing and food delivery company. And for good reason -- those businesses still drive the majority of its revenue and growth. But beneath the surface, a quieter business is starting to take shape. And it could become one of Uber's most important profit drivers over time. That business is advertising. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » A small segment with bigger-than-expected potential Uber's advertising business started as a simple idea: Help restaurants promote their listings within the Uber Eats app. For years, management viewed this as a useful but limited monetization tool. In fact, the company once believed advertising penetration in delivery would top out at around 2% of gross bookings. But that assumption is already proving too conservative. On its latestearnings call Uber said advertising penetration has already exceeded that 2% level (over $2 billion annualized revenue run rate), and the opportunity is now "much larger" than initially expected. That shift matters. When management raises its view of a business's long-term potential, it often signals that early results are exceeding expectations. And in Uber's case, the drivers of that upside are becoming clearer. Why is advertising so powerful? Unlike rides or deliveries, advertising doesn't require drivers, vehicles, or logistics. It simply monetizes demand that already exists on the platform. That makes it a fundamentally different kind of business. Every time a user opens the app to order food or request a ride, Uber has an ...
Key Points Kynam Capital sold 2,957,386 shares of Viridian Therapeutics in the fourth quarter; the estimated trade size was $81.11 million based on quarterly average pricing. Meanwhile, the quarter-end Viridian position value fell by $49.79 million, reflecting both trading and price movements. The quarter-end holding stood at 1,470,541 shares valued at $45.76 million. 10 stocks we like better than...
Key Points Kynam Capital sold 2,957,386 shares of Viridian Therapeutics in the fourth quarter; the estimated trade size was $81.11 million based on quarterly average pricing. Meanwhile, the quarter-end Viridian position value fell by $49.79 million, reflecting both trading and price movements. The quarter-end holding stood at 1,470,541 shares valued at $45.76 million. 10 stocks we like better than Viridian Therapeutics › Kynam Capital Management trimmed its stake in Viridian Therapeutics (NASDAQ:VRDN), selling 2,957,386 shares in the fourth quarter, an estimated $81.11 million transaction based on quarterly average pricing, according to a February 17, 2026, SEC filing. What happened According to a filing with the U.S. Securities and Exchange Commission dated February 17, 2026, Kynam Capital Management reduced its holding in Viridian Therapeutics by 2,957,386 shares during the fourth quarter. The estimated transaction value is $81.11 million, calculated using the average closing price for the quarter. The value of the Viridian stake at quarter-end declined by $49.79 million, a figure that includes both trading and market price effects. What else to know The fund sold shares, bringing its Viridian stake to 2.92% of 13F reportable assets under management. Top five holdings after the filing: NASDAQ:COGT: $218.99 million (14.3% of AUM) NASDAQ:VERA: $173.85 million (11.3% of AUM) NASDAQ:SNDX: $169.15 million (11.0% of AUM) NASDAQ:CLDX: $161.42 million (10.5% of AUM) NASDAQ:PCVX: $134.84 million (8.8% of AUM) As of Friday, Viridian shares were priced at $26.98, up 76% over the past year and well outperforming the S&P 500’s roughly 15% gain in the same period. Company overview Metric Value Price (as of Friday) $26.98 Market capitalization $2.8 billion Revenue (TTM) $70.79 million Net income (TTM) ($342.6 million) Company snapshot Viridian Therapeutics develops monoclonal antibody therapies, with a current focus on treatments for thyroid eye disease (TED), including lead can...
Bayern Munich scored three times in seven minutes to cruise past Union Berlin 4-0 in the Bundesliga on Saturday to stay clear at the top while edging closer to an all-time club scoring record. The Bavarian club, chasing three trophies and fresh from their midweek Champions League quarter-final qualification with a 10-2 aggregate win over Atalanta, are nine points clear at the top. Bayern have now ...
Bayern Munich scored three times in seven minutes to cruise past Union Berlin 4-0 in the Bundesliga on Saturday to stay clear at the top while edging closer to an all-time club scoring record. The Bavarian club, chasing three trophies and fresh from their midweek Champions League quarter-final qualification with a 10-2 aggregate win over Atalanta, are nine points clear at the top. Bayern have now scored 97 league goals, four short of equalling the all-time club record in the 1971-72 Bundesliga campaign. “We will get the record but the priority for me is something else,” Vincent Kompany, their coach, said. “I am not someone who likes talking about this record. I am not too interested. Your playing style does not stop because the season is coming to an end. “We must never forget what our strengths are and keep bringing them to the pitch regardless of the opponent.” Union managed to compete for half an hour before the hosts turned up the pressure, with the teenager Lennart Karl, who earned a Germany call-up this week, hitting a post. Michael Olise did better in the 42nd minute, curling a shot past Frederik Rønnow to put Bayern ahead. Serge Gnabry fired home the second goal in first-half stoppage time before the Bundesliga’s leading scorer Harry Kane added the third four minutes after the restart. Kane, chasing Robert Lewandowski’s 41-goal record in a single Bundesliga season, now has 31 league goals with seven matches remaining. Gnabry unleashed a powerful shot to bag his second goal in the 67th minute as the one-way traffic continued and Olise hit the woodwork with a low drive late in the game, before Kane nearly added another but chipped the ball wide. Second-placed Borussia Dortmund missed a penalty but scored three goals in 11 minutes late in the second half to race back from 2-0 down and snatch a 3-2 victory over visitors Hamburg. Dortmund found themselves 2-0 down in the first half with Hamburg taking a 19th-minute lead through Philip Otele’s tap-in and Albert Sa...
Chelsea are in freefall after their latest defeat - 3-0 at Everton - and now have a two‑week international break during which to stew on 10 damaging days. After suffering an 8-2 aggregate loss to Paris St‑Germain in the Champions League last 16, Chelsea's defeat at the hands of Beto and Ilman Ndiaye on Saturday means back‑to‑back Premier League losses and no wins in four in all competitions. This ...
Chelsea are in freefall after their latest defeat - 3-0 at Everton - and now have a two‑week international break during which to stew on 10 damaging days. After suffering an 8-2 aggregate loss to Paris St‑Germain in the Champions League last 16, Chelsea's defeat at the hands of Beto and Ilman Ndiaye on Saturday means back‑to‑back Premier League losses and no wins in four in all competitions. This has led to increasing scrutiny of head coach Liam Rosenior and the club as a whole, not least from vice‑captain Enzo Fernandez, who said Chelsea had lost "identity, structure and direction" since former boss Enzo Maresca left the club in January, adding the players did not understand why he left. Although Fernandez went closest to scoring and embraced Rosenior after the match, his comments paint a worrying picture. Once again on Saturday, Chelsea were outrun, error‑prone and tactically open, as Everton played through them for a comfortable win at the Hill Dickinson Stadium. The result leaves Chelsea sixth in the Premier League, still just one point behind fifth‑placed Liverpool in the race for Champions League qualification. However, Everton are now seventh and only two points behind Chelsea, part of a group of sides capable of leapfrogging the struggling giants with seven matches left to play this season. "I don't focus on the noise," Rosenior told BBC Match of the Day. "I know the reality of where I'm at and where we are at as a club and what we can achieve, which is still some amazing things. "It's been a really testing period for these lads. We've had a lot of setbacks and we have to dust ourselves down and make sure we come back fighting."
There have been countless examples but if one action epitomised Gabriel Magalhães’s commitment to the cause it came against Bayer Leverkusen in the first leg of Arsenal’s Champions League tie in Germany last week. Jarell Quansah’s shot was heading like a rocket towards David Raya’s goal until the Brazil defender intervened with a combination of neck, chin and face. It has become customary for Gabr...
There have been countless examples but if one action epitomised Gabriel Magalhães’s commitment to the cause it came against Bayer Leverkusen in the first leg of Arsenal’s Champions League tie in Germany last week. Jarell Quansah’s shot was heading like a rocket towards David Raya’s goal until the Brazil defender intervened with a combination of neck, chin and face. It has become customary for Gabriel to celebrate his blocks and last-ditch tackles by beating his chest in delight but even he needed a moment to come to his senses. “I couldn’t breathe after this,” the 28-year-old says. “I always try to do my best and I gave everything for this badge. So my teammates can see as well. If you see the block of [Riccardo] Calafiori against Everton, it was unbelievable. We try to do our best every time.” Piero Hincapié also blocked a shot with his head despite being on the ground in Arsenal’s win over Brighton this month during a game in which Gabriel made an incredible 14 clearances, including preventing a chip by Carlos Baleba from crossing the line. As Mikel Arteta has repeatedly recognised, Arsenal’s No 6 “sets the tone” in a team that recorded a 25th clean sheet in their 49th game of the campaign as Leverkusen were brushed aside on Tuesday. Gabriel has blocked 38 shots this season – 29% of the squad’s total – and is the undisputed leader of Arsenal’s defence as they prepare to face Manchester City in Sunday’s Carabao Cup final. “I’m a defender, so I need to bring this energy for my teammates, for our fans,” says Gabriel. “I give everything when I’m on the pitch. I try to push everyone. It’s going to be a big battle and I’m ready to do this.” All eyes will be on his showdown with Erling Haaland and it’s no surprise to hear that both relish the challenge of facing each other. “I think it is fun – we enjoy it,” says Gabriel. “To be honest, I enjoy every game, every striker. It is my job, so I like to battle. But he is a top player and, of course, I think he likes to play ag...
Tottenham interim head coach Igor Tudor has cleared up the viral moment where it was thought he mistakenly hugged someone thinking it was Liverpool manager Arne Slot. Last Sunday at Anfield the 47-year-old Croatian was caught by TV cameras before their 1-1 draw seemingly mixing up Tottenham's player liaison officer Allan Dixon with Slot. The images gained traction on social media and were used to ...
Tottenham interim head coach Igor Tudor has cleared up the viral moment where it was thought he mistakenly hugged someone thinking it was Liverpool manager Arne Slot. Last Sunday at Anfield the 47-year-old Croatian was caught by TV cameras before their 1-1 draw seemingly mixing up Tottenham's player liaison officer Allan Dixon with Slot. The images gained traction on social media and were used to poke fun at Tudor but, before their Premier League home game against Nottingham Forest on Sunday, he said there was no confusion at his end. Tudor said he frequently works with Dixon, who is also the brother-in-law of ex-Spurs chairman Daniel Levy, and gave him another hug before their 3-2 win over Atletico Madrid in midweek to make light of it. "I don't recognise the guy who I spend 10 hours with every day?! So I come out and don't know he is? It was a little bit ridiculous," Tudor told a news conference. "Now [on Wednesday] we did it on purpose to make a joke, because from now on I call him 'Arne'. It's not Allan, it's Arne!" Tudor said he was alerted to the incident by his family, who also thought he had accidentally confused Dixon with Slot. He added: "What happened was my son, who is 20 years old, said in Croatia everyone is laughing with you because you did this mistake. I said, 'what mistake?' and I said to him, 'you do know who the guy is?'. "So I said, 'it's Allan Dixon, I'm spending all days together with him', so I came out and he's standing in front of my bench. So what other coach can be there in front of it? It's my training zone. "He was there, I came to him to make a joke. If you understand, I came from this side [Dixon's right], I touched him and go to the other side. "When he turned I was not surprised, I was laughing. I can imagine in Croatia because maybe they don't know who Allan Dixon is."
Key Points Kynam Capital sold 1,059,375 shares of CG Oncology in the fourth quarter; the estimated trade size was $43.84 million based on quarterly average prices. Meanwhile, the quarter-end position value decreased by $41.50 million, reflecting both trading activity and price movement. The post-transaction stake stood at 945,830 shares valued at $39.27 million. 10 stocks we like better than Cg On...
Key Points Kynam Capital sold 1,059,375 shares of CG Oncology in the fourth quarter; the estimated trade size was $43.84 million based on quarterly average prices. Meanwhile, the quarter-end position value decreased by $41.50 million, reflecting both trading activity and price movement. The post-transaction stake stood at 945,830 shares valued at $39.27 million. 10 stocks we like better than Cg Oncology › Kynam Capital Management reduced its position in CG Oncology (NASDAQ:CGON), selling 1,059,375 shares in the fourth quarter for an estimated $43.84 million based on quarterly average pricing, according to a February 17, 2026, SEC filing. What happened According to a filing with the Securities and Exchange Commission dated February 17, 2026, Kynam Capital Management sold 1,059,375 shares of CG Oncology during the fourth quarter. The estimated transaction value was $43.84 million, calculated using the period's average closing price. After the sale, the fund held 945,830 shares, valued at $39.27 million at quarter-end. The net position change, reflecting both trading and price effects, was $41.50 million. What else to know The reduction brings CG Oncology to 2.51% of Kynam Capital’s 13F reportable AUM, down from 6.0% the prior quarter. Top holdings after the filing: NASDAQ:COGT: $218.99 million (14.3% of AUM) NASDAQ:VERA: $173.85 million (11.3% of AUM) NASDAQ:SNDX: $169.15 million (11.0% of AUM) NASDAQ:CLDX: $161.42 million (10.5% of AUM) NASDAQ:PCVX: $134.84 million (8.8% of AUM) As of Friday, CG Oncology shares were priced at $65.08, up 135% over the past year and well surpassing the S&P 500’s roughly 15% gain in the same period. Company overview Metric Value Market Capitalization $5.5 billion Revenue (TTM) $4 million Net Income (TTM) ($160.1 million) Price (as of Friday) $65.08 Company Snapshot CG Oncology develops and commercializes cretostimogene, a bladder-sparing therapeutic candidate for high-risk non-muscle invasive bladder cancer unresponsive to Bacillus Calm...